Organo-ID None
Organo-ID offers preclinical models for metabolic liver disease and rare diseases like citrullinemia and pyruvate decarboxylase. They also provide PDCOs that can test tumor response to treatments for individual patients, which helps oncologists treat patients in a more personalized way.
Estimated Revenue:
US$ 2,507.28 million